Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized， double-blind， phase III KEYNOTE-564 study.

帕博利珠单抗与安慰剂作为肾癌患者肾切除术后辅助治疗的比较：随机、双盲、III期KEYNOTE-564研究

作者：Toni K. Choueiri， et al.

摘要号：LBA5

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.

CANTATA: Primary analysis of a global， randomized， placebo (Pbo)-controlled， double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.

全球、随机、安慰剂对照、双盲CANTATA试验的初步分析：在免疫检查点抑制剂或抗血管生成治疗进展的晚期/转移性肾细胞癌患者中，telaglenastat（CB-839）+卡博替尼与安慰剂+卡博替尼的对比

作者：Nizar M. Tannir， et al.

摘要号：4501

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).

仑伐替尼+帕博利珠单抗或依维莫司对比舒尼替尼治疗晚期肾细胞癌患者的3期CLEAR试验的健康相关生活质量（HRQoL）分析

作者：Robert J. Motzer， et al.

摘要号：4502

Phase 2 trial of gemcitabine， cisplatin， plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.

肌层浸润性膀胱癌（MIBC）患者给予吉西他滨、顺铂+纳武利尤单抗及选择性保留膀胱治疗的2期试验：HCRN GU 16-257

作者：Matt D. Galsky， et al.

摘要号：4503

Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.

帕博利珠单抗联合吉西他滨和同步大分割放疗作为肌层浸润性膀胱尿路上皮癌（MIBC）的保膀胱治疗：一项多中心2期试验

作者：Arjun V. Balar， et al.

摘要号：4504

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.

度伐利尤单抗+tremelimumab+放疗在选择性保留膀胱治疗局限性肌层浸润性膀胱癌（MIBC）患者中的II期试验：IMMUNOPRESERVE-SOGUG试验

作者：Xavier Garcia del Muro， et al.

摘要号：4505

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

一项比较顺铂+吉西他滨加±berzosertib治疗晚期尿路上皮癌的随机II期研究

作者：Sumanta K. Pal， et al.

摘要号：4507

First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

帕博利珠单抗一线治疗不适合顺铂的晚期尿路上皮癌：2期KEYNOTE-052研究的5年反应和生存结果

作者：Peter H. O’Donnell， et al.

摘要号：4508

Inducible T-cell co-stimulatory (ICOS) receptor agonist， feladilimab (fela)， alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).

诱导性T细胞共刺激（ICOS）受体激动剂feladilimab单独或联合帕博利珠单抗：来自INDUCE-1尿路上皮癌扩展队列的结果

作者：Arjun V. Balar， et al.

摘要号：4519

A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).

SWOG S1216：一项比较雄激素剥夺疗法（ADT）+TAK-700与ADT+比卡鲁胺治疗新诊断转移性激素敏感前列腺癌（mHSPC）患者III期随机试验（NCT01809691）

作者：Neeraj Agarwal， et al.

摘要号：5001

Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

在Ra223联合恩扎鲁胺对比单独恩扎鲁胺的EORTC 1333/PEACEIII试验中，通过使用骨保护剂降低骨折率：最新的安全性分析

作者：Silke Gillessen， et al.

摘要号：5002

Ancestral characterization of the genomic landscape， comprehensive genomic profiling utilization， and treatment patterns may inform disparities in advanced prostate cancer: A large-scale analysis.

基因组图谱的祖先特征、全面的基因组图谱使用和治疗模式可能为晚期前列腺癌的差异提供信息：一项大规模分析

作者：Smruthy Sivakumar，  et al.

摘要号：5003

Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes.

非洲裔美国年轻男性前列腺特异性抗原筛查强度增加与前列腺癌预后改善的关系

作者：Edmund M. Qiao， et al.

摘要号：5004

A prospective ValiDation of the genomic classifier defines high-metastasis risk in a subset of African American men with early localized prostate cancer: VanDAAM study.

一项基因组分类的前瞻性验证分析确定非洲裔美国男性早期局限性前列腺癌的高转移风险：VanDAAM研究

作者：Kosj Yamoah， et al.

摘要号：5005

Testicular cancer in the cisplatin era: Causes of death and mortality rates in a population-based cohort.

顺铂时代的睾丸癌：基于人群队列的死亡原因和死亡率

作者：Ragnhild Hellesnes， et al.

摘要号：5006

Late relapse of germ cell tumors: Detection and treatment outcomes.

生殖细胞肿瘤晚期复发的检测和治疗结果

作者：Noah H. Richardson， et al.

摘要号：5007